Literature DB >> 14710881

Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998).

Kevin A Hahn1, Glen K King, Janet K Carreras.   

Abstract

OBJECTIVE: To determine the efficacy (durations of remission and survival) of an alternating-day radiation protocol for incompletely excised histologic grade-III solitary mast cell tumors (MCTs) in dogs.
DESIGN: Retrospective study. ANIMALS: 31 dogs. PROCEDURE: Radiation (52 Gy in an 18-fraction alternating-day protocol) was delivered to an area bordered by margins > or = 3 cm around the surgical scar and to the associated local-regional lymph nodes. Dogs were not given chemotherapeutic agents concurrently or after radiation. Information on signalment, duration of remission, and survival time was obtained from medical records.
RESULTS: Median and mean durations of remission were 27.7 and 17.0 months, respectively (range, 1 to 47 months). Median and mean durations of survival were 28 and 20 months, respectively (range, 3 to 52 months). Dogs with tumors located on the skin of the pinna, perineum, and prepuce had a median duration of remission greater than dogs with tumors located at other sites (27.7 and 14.4 months, respectively). Dogs with tumors < or = 3 cm in maximum diameter before surgery survived longer than dogs with tumors > 3 cm (31 and 24 months, respectively). The remission rate was 65% and survival rate was 71% at 1 year after treatment. Sixteen dogs that were euthanatized had complications associated with local-regional tumor progression. Systemic metastases to liver, spleen, intestine, and bone marrow were detected in 1 dog. CONCLUSIONS AND CLINICAL RELEVANCE: Without further treatment, incompletely excised grade-III mast cell tumors have high local-regional recurrence; local-regional treatment with radiation may effectively be used to manage many such tumors.

Entities:  

Mesh:

Year:  2004        PMID: 14710881     DOI: 10.2460/javma.2004.224.79

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  12 in total

1.  Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.

Authors:  Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes
Journal:  Can Vet J       Date:  2021-12       Impact factor: 1.008

2.  Modulation of mTOR signaling by radiation and rapamycin treatment in canine mast cell cancer cells.

Authors:  Morla Phan; Changseok Kim; Anthony Mutsaers; Valerie Poirier; Brenda Coomber
Journal:  Can J Vet Res       Date:  2022-01       Impact factor: 0.897

3.  Surgery and radiation therapy for extramedullary plasmacytoma of the penile mucosa in a dog.

Authors:  Jackie M Wypij; Louis-Philippe de Lorimier
Journal:  Can Vet J       Date:  2012-09       Impact factor: 1.008

4.  Intranasal mast cell tumor in the dog: A case series.

Authors:  Alison Khoo; Amy Lane; Ken Wyatt
Journal:  Can Vet J       Date:  2017-08       Impact factor: 1.008

5.  Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).

Authors:  Galina V Ilyinskaya; Elena V Mukhina; Alesya V Soboleva; Olga V Matveeva; Peter M Chumakov
Journal:  Front Vet Sci       Date:  2018-06-04

6.  Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.

Authors:  Jaime A Olsen; Maurine Thomson; Kathleen O'Connell; Ken Wyatt
Journal:  Vet Med Sci       Date:  2018-05-24

Review 7.  Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.

Authors:  Michael Willmann; Emir Hadzijusufovic; Olivier Hermine; Mauro Dacasto; Laura Marconato; Karin Bauer; Barbara Peter; Susanne Gamperl; Gregor Eisenwort; Erika Jensen-Jarolim; Mathias Müller; Michel Arock; David M Vail; Peter Valent
Journal:  Vet Comp Oncol       Date:  2018-09-24       Impact factor: 2.613

8.  Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.

Authors:  Susanne Gamperl; Gabriele Stefanzl; Barbara Peter; Dubravka Smiljkovic; Karin Bauer; Michael Willmann; Peter Valent; Emir Hadzijusufovic
Journal:  Vet Comp Oncol       Date:  2019-08-13       Impact factor: 2.613

Review 9.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

Review 10.  Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.

Authors:  Michael Willmann; Vilma Yuzbasiyan-Gurkan; Laura Marconato; Mauro Dacasto; Emir Hadzijusufovic; Olivier Hermine; Irina Sadovnik; Susanne Gamperl; Mathias Schneeweiss-Gleixner; Karoline V Gleixner; Thomas Böhm; Barbara Peter; Gregor Eisenwort; Richard Moriggl; Zhixiong Li; Mohamad Jawhar; Karl Sotlar; Erika Jensen-Jarolim; Veronika Sexl; Hans-Peter Horny; Stephen J Galli; Michel Arock; David M Vail; Matti Kiupel; Peter Valent
Journal:  Front Vet Sci       Date:  2021-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.